If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
Abstract | Full Text: PDF (Size: 123K) | Related Articles | Citation Tracking  Amphetamine-derived Designer Drugs: Metabolism and Screening Procedures Amphetamin-verwandte Designer-Drogen: Metabolismus und Screening Verfahren Copyright Blackwell Verlag KEYWORDS amphetamine • designer drugs • metabolism • screening procedures KEYWORDS Amphetamine • Designer Drogen • Metabolismus • Screening Verfahren ABSTRACTSummary: This paper reviews studies on the metabolism, including its cytochrome P450 isoenzyme dependency, and on screening procedures for detection of the amphetamine-derived designer drugs MDA (methylenedioxyamphetamine, R,S-1-(3',4'-methylenedioxyphenyl)-2-propanamine), MDMA (R,S-methylenedioxymethamphetamine) and MDE (R,S-methylenedioxyethylamphetamine) as well as BDB (benzodioxolylbutanamine; R,S-1-(1',3'-benzodioxol-5'-yl)-2-butanamine or R,S-1-(3',4'-methylenedioxyphenyl)-2-butanamine) and MBDB (R,S-N-methyl-benzodioxolylbutanamine) in blood and urine. Only mass spectral procedures using gas chromatography, liquid chromatography or capillary electrophoresis for separation are described in detail. For other procedures like immunoassays or chromatography with other detectors suitable references including reviews are cited. ABSTRACTZusammenfassung: In diesem Übersichtsartikel werden Untersuchungen referiert zum Metabolismus einschließlich seiner Abhängigkeit von Cytochrom P450-Isoenzymen von Amphetamin-verwandten Designer-Drogen MDA (Methylendioxyamphetamin, R,S-1-(3',4'-Methylendioxyphenyl)-2-propanamin), MDMA (R,S-Methylendioxymethamphetamin) und MDE (R,S-Methylendioxyethylamphetamin) sowie BDB (Benzodioxolylbutanamin; R,S-1-(1',3'-Benzodioxol-5'-yl)-2-butanamin oder R,S-1-(3',4'-Methylendioxyphenyl)-2-butanamin) und MBDB (R,S-N-Methyl-benzodioxolylbutanamin). Des Weiteren werden Screening Verfahren zum Nachweis dieser Designer Drogen in Blut und Urin vorgestellt. Lediglich massenspektrometrische Verfahren mit Trennung durch Gaschromatographie, Flüssigchromatographie oder Kapillarelektrophorese werden detailliert besprochen, während für andere Verfahren wie Immunoassays oder Chromatographie mit anderen Detektoren geeignete Literaturstellen und Reviews zitiert werden. |  |
